Advanced search
1 file | 574.67 KB Add to list

Scheduled maintenance: Publication downloads temporarily unavailable.

Due to maintenance publication downloads will not be available on:

  • Wednesday, March 27, 17:00 – 21:00
  • Thursday, March 28, 17:00 – 21:00

Exports of lists, FWO and BOF information will remain available.

For any questions, please contact biblio@ugent.be. Apologies for any inconveniences, and thank you for your understanding.

Vaccine-associated enhanced disease : case definition and guidelines for data collection, analysis, and presentation of immunization safety data

(2021) VACCINE. 39(22). p.3053-3066
Author
Organization
Abstract
This is a Brighton Collaboration Case Definition of the term & ldquo;Vaccine Associated Enhanced Disease & rdquo; to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. (c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords
RESPIRATORY SYNCYTIAL VIRUS, MULTIPLE ORGAN DYSFUNCTION, INTERNATIONAL CONSENSUS DEFINITIONS, FAILURE ASSESSMENT SCORE, SEVERE DENGUE DISEASE, SYNDROME CORONAVIRUS, MEASLES-VIRUS, IMMUNE-RESPONSES, INFLAMMATORY CYTOKINES, EMERGENCY-DEPARTMENT, Adverse event, Immunization, Guidelines, Case definition, Vaccine, Enhanced disease, Respiratory, Systemic disease

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 574.67 KB

Citation

Please use this url to cite or link to this publication:

MLA
Munoz, FM, et al. “Vaccine-Associated Enhanced Disease : Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data.” VACCINE, vol. 39, no. 22, 2021, pp. 3053–66, doi:10.1016/j.vaccine.2021.01.055.
APA
Munoz, F., Cramer, J., Dekker, C., Dudley, M., Graham, B., Gurwith, M., … Lambert, P. (2021). Vaccine-associated enhanced disease : case definition and guidelines for data collection, analysis, and presentation of immunization safety data. VACCINE, 39(22), 3053–3066. https://doi.org/10.1016/j.vaccine.2021.01.055
Chicago author-date
Munoz, FM, JP Cramer, CL Dekker, MZ Dudley, BS Graham, M Gurwith, B Law, et al. 2021. “Vaccine-Associated Enhanced Disease : Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data.” VACCINE 39 (22): 3053–66. https://doi.org/10.1016/j.vaccine.2021.01.055.
Chicago author-date (all authors)
Munoz, FM, JP Cramer, CL Dekker, MZ Dudley, BS Graham, M Gurwith, B Law, S Perlman, F Polack, SV Anderson, JM Spergel, Eva Van Braeckel, B Ward, AM Didierlaurent, and PH Lambert. 2021. “Vaccine-Associated Enhanced Disease : Case Definition and Guidelines for Data Collection, Analysis, and Presentation of Immunization Safety Data.” VACCINE 39 (22): 3053–3066. doi:10.1016/j.vaccine.2021.01.055.
Vancouver
1.
Munoz F, Cramer J, Dekker C, Dudley M, Graham B, Gurwith M, et al. Vaccine-associated enhanced disease : case definition and guidelines for data collection, analysis, and presentation of immunization safety data. VACCINE. 2021;39(22):3053–66.
IEEE
[1]
F. Munoz et al., “Vaccine-associated enhanced disease : case definition and guidelines for data collection, analysis, and presentation of immunization safety data,” VACCINE, vol. 39, no. 22, pp. 3053–3066, 2021.
@article{8690136,
  abstract     = {{This is a Brighton Collaboration Case Definition of the term & ldquo;Vaccine Associated Enhanced Disease & rdquo; to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission.

(c) 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).}},
  author       = {{Munoz, FM and Cramer, JP and Dekker, CL and Dudley, MZ and Graham, BS and Gurwith, M and Law, B and Perlman, S and Polack, F and Anderson, SV and Spergel, JM and Van Braeckel, Eva and Ward, B and Didierlaurent, AM and Lambert, PH}},
  issn         = {{0264-410X}},
  journal      = {{VACCINE}},
  keywords     = {{RESPIRATORY SYNCYTIAL VIRUS,MULTIPLE ORGAN DYSFUNCTION,INTERNATIONAL CONSENSUS DEFINITIONS,FAILURE ASSESSMENT SCORE,SEVERE DENGUE DISEASE,SYNDROME CORONAVIRUS,MEASLES-VIRUS,IMMUNE-RESPONSES,INFLAMMATORY CYTOKINES,EMERGENCY-DEPARTMENT,Adverse event,Immunization,Guidelines,Case definition,Vaccine,Enhanced disease,Respiratory,Systemic disease}},
  language     = {{eng}},
  number       = {{22}},
  pages        = {{3053--3066}},
  title        = {{Vaccine-associated enhanced disease : case definition and guidelines for data collection, analysis, and presentation of immunization safety data}},
  url          = {{http://doi.org/10.1016/j.vaccine.2021.01.055}},
  volume       = {{39}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: